Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tusamitamab Ravtansine + Ramucirumab +/- Pembrolizumab in Metastatic NSQ NSCLC
NCT04394624Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Aug 2020
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of tusamitamab ravtansine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sanofi. Primary endpoints: Dose-Limiting Toxicity and Objective Response Rate up to 130 weeks. Started Aug 2020; status: terminated.
02
Drugs
tusamitamab ravtansine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04394624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04394624.